[Ip-health] KEI, KEI Europe, and Essential Inventions ask five companies for licenses to HCV patents

Claire Cassedy claire.cassedy at keionline.org
Wed Mar 18 11:55:10 PDT 2015


KEI, KEI Europe, and Essential Inventions ask five companies for licenses
to HCV patents

Submitted by Claire Cassedy [1] on 18. March 2015 - 13:36

On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted
proposals for global voluntary licences for all patents necessary for
hepatitis C (HCV) medicines to five drug companies -- AbbVie, Bristol-Myers
Squibb, Gilead, Janssen, and Merck.

The proposed licences would permit the manufacture, import, export and sale
of generic HCV medicines in every country in the world. Significantly, the
proposal puts forth an innovative royalty structure that accounts for
income disparity, HCV incidence rate, and the differing health statuses of
HCV patients in countries around the world, and provides a detailed annex
demonstrating the royalties that companies would stand to earn in various
specific countries for treating patients at different stages of infection.

-Voluntary Licence Request to Abbvie on HCV Patents [

-Voluntary Licence Request to Bristol-Myers Squibb on HCV Patents [

-Voluntary Licence Request to Gilead on HCV Patents [

-Voluntary Licence Request to Janssen on HCV Patents [

-Voluntary Licence Request to Merck on HCV Patents [

Earlier, KEI Europe sought voluntary HCV patent licenses from BMS and
Gilead for the territory of Romania, and subsequently asked the Government
of Romania to petition the court for compulsory licenses on HCV patents. A
copy of the KEI Europe press release is here (html [
http://keieurope.org/press/pr20150318Romania-HCV-CL.html], pdf [

For more information, or if you have any questions, contact Andrew Goldman,
Counsel for Policy and Legal Affairs at KEI via email at andrew.goldman[at]

More information about the Ip-health mailing list